We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+16.66%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.04B
AUM Growth
+$465M
(+29%)
Cap. Flow
+$311M
Cap. Flow
% of AUM
15.21%
Top 10 Holdings %
Top 10 Hldgs %
65.12%
Holding
37
New
14
Increased
6
Reduced
7
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$108M |
| 2 |
Universal Health Services
UHS
|
+$83.4M |
| 3 |
GSK
GSK
|
+$55.4M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$49.3M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$44.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$82.5M |
| 2 |
Nektar Therapeutics
NKTR
|
+$72.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$58.3M |
| 4 |
Orthofix Medical
OFIX
|
+$45.4M |
| 5 |
Gilead Sciences
GILD
|
+$40.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Sarepta Therapeutics
SRPT
$1.64B
| $16.7M | 0.82% |
300,000
-1,100,000
| -79% | -$58.3M |
|
|
KTWO
27
DELISTED
K2M Group Holdings, Inc
KTWO
| $15.3M | 0.75% |
+850,000
| New | +$16.1M |
|
|
WMGI
28
DELISTED
Wright Medical Group Inc
WMGI
| $12.8M | 0.62% |
+575,000
| New | +$14.2M |
|
29
Atara Biotherapeutics
ATRA
$73.6M
| $9.69M | 0.47% |
21,420
| – | – |
|
|
DRNA
30
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $9.03M | 0.44% |
+1,000,000
| New | +$7.36M |
|
31
Option Care Health
OPCH
$3.36B
| $7.39M | 0.36% |
635,050
-940,000
| -60% | -$9.49M |
|
32
Prothena Corp
PRTA
$440M
| $4.69M | 0.23% |
+125,000
| New | +$6.36M |
|
|
MNK
33
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $2.37M | 0.12% |
+105,000
| New | +$2.82M |
|
34
Surgery Partners
SGRY
$2.08B
| $1.64M | 0.08% |
+135,084
| New | +$1.29M |
|
|
35
Gilead Sciences
GILD
$163B
| – | – |
-500,000
| Closed | -$40.5M |
|
|
36
Perrigo
PRGO
$1.43B
| – | – |
-975,000
| Closed | -$82.5M |
|
|
BIOL
37
DELISTED
Biolase, Inc.
BIOL
| – | – |
-427
| Closed | -$3.21M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2017 Portfolio in Review
As of Q4 2017, Camber Capital Management held 37 positions worth $2.04B, up 29% from $1.58B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Camber Capital Management deployed $311M of net new capital in Q4 2017, opening 14 new positions and adding to 6 existing holdings. Its largest new stake was Allergan plc: 600,000 shares worth $98.1M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 62% a quarter earlier.
On the sell side, the largest reduction was Nektar Therapeutics, an estimated $72.9M trimmed.
- Camber Capital Management's largest Q4 2017 buy was Allergan plc: 600,000 shares worth $98.1M.
- Camber Capital Management added most to TESARO, Inc. in Q4 2017, an estimated $44.1M increase.
- Camber Capital Management's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $72.9M.
- Camber Capital Management fully exited Perrigo in Q4 2017, selling an estimated $82.5M.
- Camber Capital Management's ten largest holdings make up 65% of its $2.04B portfolio in Q4 2017.
- Camber Capital Management opened 14 new positions and closed 3 in Q4 2017.
- Camber Capital Management's portfolio value rose 29% quarter-over-quarter to $2.04B.
Based on Camber Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.